Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 5.03
INSM's Cash to Debt is ranked higher than
69% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: 42.14 vs. INSM: 5.03 )
INSM' s 10-Year Cash to Debt Range
Min: 0.86   Max: No Debt
Current: 5.03

F-Score: 4
Z-Score: 5.43
M-Score: 3.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -478.39
INSM's Operating margin (%) is ranked higher than
59% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. INSM: -478.39 )
INSM' s 10-Year Operating margin (%) Range
Min: -813000   Max: -83.62
Current: -478.39

-813000
-83.62
Net-margin (%) -487.59
INSM's Net-margin (%) is ranked higher than
59% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. INSM: -487.59 )
INSM' s 10-Year Net-margin (%) Range
Min: -779300   Max: 1140.94
Current: -487.59

-779300
1140.94
ROE (%) -39.12
INSM's ROE (%) is ranked higher than
65% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. INSM: -39.12 )
INSM' s 10-Year ROE (%) Range
Min: -404.46   Max: 95.51
Current: -39.12

-404.46
95.51
ROA (%) -31.77
INSM's ROA (%) is ranked higher than
66% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. INSM: -31.77 )
INSM' s 10-Year ROA (%) Range
Min: -329.28   Max: 93.41
Current: -31.77

-329.28
93.41
ROC (Joel Greenblatt) (%) -3036.15
INSM's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 881 Companies
in the Global Biotechnology industry.

( Industry Median: -200.53 vs. INSM: -3036.15 )
INSM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -679662.5   Max: -734.3
Current: -3036.15

-679662.5
-734.3
Revenue Growth (%) -14.10
INSM's Revenue Growth (%) is ranked higher than
68% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. INSM: -14.10 )
INSM' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 217.5
Current: -14.1

0
217.5
EBITDA Growth (%) 48.80
INSM's EBITDA Growth (%) is ranked higher than
98% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. INSM: 48.80 )
INSM' s 10-Year EBITDA Growth (%) Range
Min: -59.4   Max: 48.8
Current: 48.8

-59.4
48.8
EPS Growth (%) 48.40
INSM's EPS Growth (%) is ranked higher than
97% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. INSM: 48.40 )
INSM' s 10-Year EPS Growth (%) Range
Min: -59.5   Max: 48.4
Current: 48.4

-59.5
48.4
» INSM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

INSM Guru Trades in Q3 2013

Steven Cohen 362,600 sh (New)
» More
Q4 2013

INSM Guru Trades in Q4 2013

Steven Cohen 492,957 sh (+35.95%)
» More
Q1 2014

INSM Guru Trades in Q1 2014

John Burbank 10,328 sh (New)
Steven Cohen 80,000 sh (unchged)
Steven Cohen 203,000 sh (-58.82%)
» More
Q2 2014

INSM Guru Trades in Q2 2014

Jim Simons 48,587 sh (New)
Steven Cohen 651,687 sh (unchged)
John Burbank Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INSM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-06-30 Sold Out 0.01%$12.1 - $19.73 $ 13.93-5%0
John Burbank 2014-03-31 New Buy0.01%$15.905 - $21.54 $ 13.93-26%10328
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.20
INSM's P/B is ranked higher than
72% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 6.10 vs. INSM: 4.20 )
INSM' s 10-Year P/B Range
Min: 0.45   Max: 105
Current: 4.2

0.45
105
EV-to-EBIT -8.25
INSM's EV-to-EBIT is ranked higher than
74% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSM: -8.25 )
INSM' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -8.25

Shiller P/E 30.40
INSM's Shiller P/E is ranked higher than
96% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSM: 30.40 )
INSM' s 10-Year Shiller P/E Range
Min: 21.54   Max: 44.19
Current: 30.4

21.54
44.19
Current Ratio 5.31
INSM's Current Ratio is ranked higher than
78% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. INSM: 5.31 )
INSM' s 10-Year Current Ratio Range
Min: 0.53   Max: 54.49
Current: 5.31

0.53
54.49
Quick Ratio 5.31
INSM's Quick Ratio is ranked higher than
79% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 3.87 vs. INSM: 5.31 )
INSM' s 10-Year Quick Ratio Range
Min: 0.53   Max: 54.49
Current: 5.31

0.53
54.49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.25
INSM's Price/Net Cash is ranked higher than
88% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 965.00 vs. INSM: 8.25 )
INSM' s 10-Year Price/Net Cash Range
Min: 0.57   Max: 197.5
Current: 8.25

0.57
197.5
Price/Net Current Asset Value 8.25
INSM's Price/Net Current Asset Value is ranked higher than
87% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 217.00 vs. INSM: 8.25 )
INSM' s 10-Year Price/Net Current Asset Value Range
Min: 0.54   Max: 940
Current: 8.25

0.54
940
Price/Tangible Book 7.45
INSM's Price/Tangible Book is ranked higher than
75% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9.20 vs. INSM: 7.45 )
INSM' s 10-Year Price/Tangible Book Range
Min: 0.51   Max: 90
Current: 7.45

0.51
90
Forward Rate of Return (Yacktman) -5.93
INSM's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: -9.52 vs. INSM: -5.93 )
INSM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -5.93

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IM8N.Germany
Insmed, Inc. is a development-stage biopharmaceutical company. The Company develops inhaled treatments for serious lung infections. Its proprietary liposomal technology is designed specifically for delivery of pharmaceuticals to the lung and it believe it provides for potential improvements to the conventional inhalation methods of delivering drug to the pulmonary system. These potential advantages include improvements in efficacy, safety and patient convenience. Its product candidate, ARIKACE (liposomal amikacin for inhalation), is a differentiated, inhaled antibiotic supported by positive Phase 2 results for treating serious lung infections due to susceptible bacteria. ARIKACE is considered a New Chemical Entity (NCE) by the United States (U.S.) Food and Drug Administration, or FDA, mainly due to its patented liposomal technology. There are two separate components to the delivery technology for ARIKACE. It has a proprietary protein product, IPLEX (mecaserminrinfabate, recombinant DNA origin, and injection), a complex of recombinant human IGF-1 and its binding protein IGFBP-3 (rhIGF-1/rhIGFBP-3). IPLEX has been studied as a treatment for several serious medical conditions such as myotonic muscular dystrophy (MMD) and ALS. It is currently being evaluated in the treatment of retinopathy of prematurity (ROP). It has three other compounds for which it are not pursuing further development on its own, Inhaled CISPLATIN Lipid Complex, rhIGFBP-3 and INSM-18, all of which are in early stage development. Inhaled CISPLATIN Lipid Complex is a novel sustained-release formulation of CISPLATIN in a lipid-based complex designed specifically for administration via inhalation for cancers affecting the lung. ARIKACE is manufactured by a third-party contract manufacturing organization using the technology developed and optimized within its company. The contract manufacturer is familiar with complex formulations such as ARIKACE and has the facilities and equipment to support the further development of the product. The Company and the contract manufacturer must comply with applicable FDA regulations relating to the FDA's cGMP regulations. The Company faces competition from many different areas including commercial pharmaceutical, biotech and device companies, academic institutions and scientists, other smaller or earlier stage companies and non-profits organizations developing anti-infective drugs and drugs for respiratory diseases.
» More Articles for INSM

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CEO Buys Highlight: TPGI, INSM, EQU, FCEL Jan 13 2013 
INSMED Inc -- A Merger Ruined its Net-Net Status Feb 02 2011 
Insmed Inc. Reports Operating Results (10-Q) Nov 03 2010 
Insmed Inc. Reports Operating Results (10-Q) Aug 04 2010 
Insmed Inc. Reports Operating Results (10-Q) May 06 2010 
Jim Simons Low P/E Stocks: Insmed Inc., Paragon Shipping Inc., The Student Loan Corp., Hellenic Tele Apr 28 2010 
frankvis note on INSM Feb 08 2010 
8 Cheap Stocks Below Net Net Working Capital Dec 14 2009 
Insmed Inc. Reports Operating Results (10-Q) Nov 09 2009 

More From Other Websites
INSMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 18 2014
Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares Aug 18 2014
Insmed Incorporated (INSM) in Focus: Stock Up 10.9% Aug 14 2014
INSMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 13 2014
Insmed Announces Pricing of Public Offering of Common Stock Aug 12 2014
INSMED INC Financials Aug 12 2014
Insmed Announces Proposed Public Offering of Common Stock Aug 11 2014
INSMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 06 2014
Insmed Reports Second Quarter 2014 Financial Results Aug 06 2014
INSMED INC Files SEC form 10-Q, Quarterly Report Aug 06 2014
Insmed (INSM) Falls: Stock Tanks 26.6% Aug 05 2014
Dow Breaks Four-Day Losing Streak As Calm Restores Last Week's Jittery Market Aug 04 2014
Why Insmed (INSM) Stock Is Plunging Today Aug 04 2014
[$$] Insmed's Arikayce Faces Longer Wait Aug 04 2014
Insmed Inc to discuss Regulatory Strategy Update for ARIKAYCE Call scheduled for 8:30 am ET today Aug 04 2014
INSMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 04 2014
Insmed Provides Regulatory Update for ARIKAYCE Aug 04 2014
Trade sees Insmed on solid ground Jul 14 2014
INSMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 11 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK